---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-22-000006"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2022-02-22T23:59:59+00:00"
generated_at: "2026-06-27T06:09:48.601166+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q3 FY2022 revenue flat at $7.8B; GAAP EPS $1.10 (+17%), non-GAAP EPS $1.37 (+6%)

## Summary
- Revenue $7.763B flat YoY; organic growth 2%; COVID-19 impact on U.S. procedure volumes.
- GAAP diluted EPS $1.10 (+17%); non-GAAP diluted EPS $1.37 (+6%), a penny above consensus.
- Q4 guidance: organic revenue growth ~5.5%; non-GAAP EPS $1.56-$1.58.
- Diabetes segment revenue down 7% as reported (-5% organic) driven by U.S. declines.
- Cardiovascular up 3% organic; Medical Surgical up 1% organic; Neuroscience up 2% organic.

## SEC filing metadata
- accession: 0001613103-22-000006
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2022-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310322000006/0001613103-22-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310322000006/mdt-20220222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-22-000006
- JSON: https://secwatch.observer/filing/0001613103-22-000006.json
- Plain text: https://secwatch.observer/filing/0001613103-22-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.